COMMUNIQUÉS West-GlobeNewswire

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04/11/2025
Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual [...]
Standard BioTools Reports Third Quarter 2025 Financial Results
04/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended September 30, 2025. [...]
OnKure Therapeutics to Participate in Upcoming Investor Conferences
04/11/2025
BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that [...]
OrthoPediatrics to Participate in Upcoming Conferences
04/11/2025
WARSAW, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, a company focused [...]
ImmuCell Announces Onboarding of New CEO and Related Management Changes
04/11/2025
PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
04/11/2025
Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 [...]
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
04/11/2025
FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of November 1, 2025 [...]
Ceribell Reports Third Quarter 2025 Financial Results
04/11/2025
SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
04/11/2025
Delivered quarterly XDEMVY ® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring strong commercial [...]
Sight Sciences to Present at Two Upcoming Investor Conferences
04/11/2025
MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Progress Update on BioPorto’s Adult Clinical Study
04/11/2025
November 4, 2025 Announcement no. 21 Progress Update on BioPorto’s Adult Clinical Study Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced [...]
Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025
04/11/2025
November 4, 2025 Announcement no. 22 Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025 Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” [...]
Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs
04/11/2025
November 4, 2025 Announcement no. 23 Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“ [...]
CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025
04/11/2025
SAN RAMON, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report fourth quarter and full year 2025 financial results on Thursday, [...]
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
04/11/2025
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./ [...]
Anaptys Announces Participation in November Investor Conferences
04/11/2025
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president [...]
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
04/11/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/11/2025
SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation
04/11/2025
Châtillon, France, le 4 novembre (22 :30 CET) 2025 DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market [...]

Pages